Takara begins leukaemia gene therapy trial in Japan
This article was originally published in Scrip
Executive Summary
Takara Bio has begun the first clinical trial in Japan with an ex vivo gene therapy, which involves the use of genetically modified donor T-cells to reduce the risk of graft-versus-host disease (GvHD) in leukaemia patients.